Deutsche Bank analyst George Hill upgraded CVS Health to Buy from Hold with an unchanged price target of $66. The firm believes both the company’s earnings and multiple are now likely near trough levels. CVS has taken steps to turn the company towards improving profitability, the analyst tells investors in a research note. Following an analysis of the managed care segment, Deutsche thinks an earnings recovery is both achievable and will outpace Street expectations.
previous post